Clinical Trials Logo

Opioid Withdrawal clinical trials

View clinical trials related to Opioid Withdrawal.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04731935 Completed - Opioid-use Disorder Clinical Trials

Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

Start date: March 18, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.

NCT ID: NCT04470050 Completed - Opioid Withdrawal Clinical Trials

Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal

Start date: June 9, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance. The opioid (morphine) maintenance phase (Phase 1b) included Days 1-5; the randomized BXCL501/placebo phase (Phase 2) included Days 6-12. The randomized phase was followed by 2 sequential days, Days 13 and 14, utilizing treatment of BXCL501-placebo sublingual films and morphine-placebo capsules for all subjects who remained in the study.

NCT ID: NCT04238754 Completed - Opioid Use Disorder Clinical Trials

Oral Cannabidiol for Opioid Withdrawal

Start date: November 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This pilot study will examine the safety of the cannabinoid cannabidiol (Epidiolex) in a human laboratory model of clinically relevant withdrawal. The study will be a residential within-subject comparison; all participants will receive placebo dosing and active cannabidiol. Results may be used to support an R01 grant application to more closely examine this hypothesis.

NCT ID: NCT04218240 Completed - Opioid Withdrawal Clinical Trials

Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal

PGB-LOF
Start date: December 17, 2020
Phase: Phase 2
Study type: Interventional

A phase II double-blind placebo-controlled parallel group clinical trial that will randomize 90 subjects to investigate whether pregabalin (PGB) combined with Lofexidine (LFX) can reduce opioid withdrawal-related subjective effects, and investigate, whether the PGB/LFX combination can increase the proportion of patients with an opioid use disorder (OUD) who complete detoxification and transition to antagonist treatment with extended-release injectable naltrexone (XR-NTX).

NCT ID: NCT04140955 Completed - Postoperative Pain Clinical Trials

Opioid Tapering After Spine Surgery

Start date: October 22, 2019
Phase: N/A
Study type: Interventional

The effect of a tapering plan combined with telephone counselling to assist patients in opioid tapering after surgery remains unexplored. A prospective, randomized controlled trial investigating the effect of a tapering plan in combination with telephone counselling in patients scheduled for spine surgery on a degenerative basis is therefore conducted.

NCT ID: NCT04126083 Completed - Opioid Withdrawal Clinical Trials

Lofexidine for Adults Undergoing Lumbar Spine Surgery

Start date: September 1, 2019
Phase: Phase 4
Study type: Interventional

The primary objective is to investigate the effects of lofexidine in adults undergoing opioid tapering prior to elective lumbar spine surgery.

NCT ID: NCT04080037 Completed - Pain Clinical Trials

Assessing Opioid Care Practices Using CPV Patient Simulation Modules

Start date: September 3, 2019
Phase: N/A
Study type: Interventional

This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback. The cases and feedback have been designed to align with the latest CDC opioid guidelines. The study will also measure the impact of gaming-inspired competition and motivation, including a weekly leaderboard, to improve evidence-based care decisions. The quality of care decisions will be measured in the simulations and in a multiple-choice assessment administered before and after the patient simulations.

NCT ID: NCT04075214 Completed - Opioid-use Disorder Clinical Trials

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

Start date: November 19, 2019
Phase: N/A
Study type: Interventional

Clinical performance data for transcutaneous auricular neurostimulation (tAN) as a method to aid in the reduction of symptoms associated with opioid withdrawal in order to support clinical substantial equivalence to a predicate device.

NCT ID: NCT04049799 Completed - Opioid-use Disorder Clinical Trials

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

MOTHER DYAD
Start date: August 8, 2019
Phase:
Study type: Observational

This study will compare medically-supervised withdrawal (MSW, 'detoxification') to opioid agonist treatment (OAT, 'maintenance') with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and neonatal outcomes. Outcomes will be assessed during pregnancy, at birth and for 12 months postpartum. This study has the potential to impact health service policy and practices in terms of the treatment options of pregnant women with opioid use disorder.

NCT ID: NCT03789214 Completed - Sleep Disturbance Clinical Trials

Medical Management of Sleep Disturbance During Opioid Tapering

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients with opioid use disorder (OUD) undergoing supervised withdrawal. This study is designed as a dose-finding study of SUVO compared to placebo. Briefly, OUD patients seeking supervised withdrawal will be admitted into a clinical research unit and stabilized onto buprenorphine for three days before being randomly assigned to study condition. All participants will then undergo a routine four-day buprenorphine taper, followed by a four-day post-taper phase. Participants will be randomized to receive either placebo, Low Dose SUVO, or High Dose SUVO and the investigators hypothesize that one or both doses of SUVO will improve total sleep time relative to placebo. Patients will attend a single follow-up session, 5-10 days following discharge.